[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365040-105":3,"detail-sidebar-cat-0-en-105":72,"doc-detail-365040-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":65,"head_meta":67,"extra_data":69,"updated_unix":71},105,"en","targeting-mdm2-p53-interaction-for-breast-cancer-therapy-review","Targeting MDM2-p53 interaction for breast cancer therapy - Review","","Breast cancer is a significant global concern with limited effective options, and current chemotherapy can cause substantial complications. Advances in targeted molecular therapies have focused on the murine double minute 2 proto-oncogene (MDM2)–tumor protein 53 (TP53) pathway. This review evaluates how inhibiting MDM2 can restore TP53 activity in breast cancer cells using clinical studies, reviews, and trials. TP53 is a tumor suppressor regulated by MDM2-mediated proteasomal degradation; cancer cells often overexpress MDM2, reducing TP53 levels. Three strategies are discussed to control MDM2 upregulation for wild-type or mutated TP53, with MDM2 inhibitors combined with existing chemotherapy, and the need for high-quality clinical trials is emphasized.",{"@graph":14,"@context":64},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-mdm2-p53-interaction-for-breast-cancer-therapy-review/365040/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-mdm2-p53-interaction-for-breast-cancer-therapy-review/365040.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58],{"name":59,"@type":60,"acceptedAnswer":61},"What evidence base does the review draw on, and what limitation is highlighted?","Question",{"text":62,"@type":63},"The review examines efficacy using clinical studies, reviews, and trials that address MDM2 inhibition and TP53 restoration. It notes that few clinical and preclinical studies using MDM2 inhibitors have been conducted, requiring high-quality clinical trials to support therapeutic potential.","Answer","https://schema.org",{"og:url":32,"og:type":66,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":68,"canonical":32},"index,follow",{"doc_id":70,"site_id":7},365040,1792321038,{"code":4,"msg":73,"data":74},"success",[75,79,83,87,92,97,102,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":76,"show_sort_weight":77,"slug":78},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":80,"show_sort_weight":81,"slug":82},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Exam",70,"exam",{"id":88,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},5,"Comic",60,"comic",{"id":93,"doc_module":4,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},6,"Technology",50,"technology",{"id":98,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},7,"Healthcare",40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},8,30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":88,"slug":121},19,"General","general",{"code":4,"msg":73,"data":123},{"doc_id":70,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ONCOLOGY RESEARCH 2025 33(4): 851-861 REVIEW  \nTargeting MDM2-p53 interaction for breast cancer therapy  \nAMJAD YOUSUF 1; NAJEEB ULLAH KHAN2,*  \n1 Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taibah University, Madinah, 41477, Saudi Arabia  \n2 Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, Peshawar, 25130, Pakistan Key words: Breast cancer, Murine double minute 2 proto-oncogene (MDM2), Tumor protein 53(TP53), Targeted therapy  \nAbstract: Breast cancer is a signiﬁcant global concern, with limited effective treatment options. Therefore, therapies with high efﬁcacy and low complications, unlike the existing chemotherapies, are urgently required. To address this issue, advances have been made in therapies targeting molecular pathways related to the murine double minute 2 protooncogene (MDM2)-tumor proteinp53 (TP53) interaction. This review aims to investigate the efﬁcacy of MDM2 inhibition in restoring TP53 activity in breast cancer cells, as evidenced by clinical studies, reviews, and trials. TP53 is a tumor suppressor and MDM2 facilitates proteasomal degradation of TP53 . MDM2 and TP53 activity is tightly regulated. However, cancerous breast cells overexpress MDM2 through ﬁve hypothesized mechanisms. Consequently, TP53 levels decrease with increased tumor cell proliferation. Three strategies have been identiﬁed for controlling MDM2 upregulation in cells with wild-type or mutated TP53 . MDM2 inhibitors (MDM2i) are administered in combination with existing chemotherapies to reduce their effects on healthy cells. Few clinical and preclinical studies have been conducted using MDM2i, which necessitates high-quality clinical trials to support their therapeutic potential in breast cancer therapy.  \nIntroduction  \nBreast cancer is a signiﬁcant global concern, particularly for women. According to reports from the World Health Organization (WHO), breast cancer alone accounted for 2.3 million cases worldwide, causing 670,000 deaths in 2022 [1] . The mammary glands are bilaterally distributed and superﬁcially positioned in the pectoralis major muscle [2] . They consist of lobules and a network of milk-producing epithelial structures. Lobules further aggregate to form lobes interspersed with adipose tissue. Cooper’s ligaments, which comprise ﬁbrous connective tissue, provide structural support by anchoring the breasts to the underlying musculofascial layer [2] . In most cases, breast cancer occurs within the ductal epithelium and results in ductal carcinoma. However, some patients develop malignancy in the lobules called lobular carcinoma.  \nBreast cancer is estimated to affect one in eight women and accounts for one in every 39 deaths in females in the United States [3] . A recent study reported that breast cancer  \n*Address correspondence to: Najeeb Ullah Khan, [najeebkhan@aup.edu.pk](najeebkhan@aup.edu.pk)  \nReceived: 25 September 2024; Accepted: 19 December 2024;  \nPublished: 19 March 2025  \nwas the second most common cancer after lung cancer among new cancer in females in 2022 [4] . The predisposition towards developing breast cancer in women increases with age [5] . The incidence rate in women aged between 20 and 24 years is approximately 1.5 cases per 100,000 females, and surges to 421.3 cases per 100,000 in women aged 75–79 years. Only 5% of the reported cases involved women aged \u003C40 years. The median age at breast cancer diagnosis is 61 years in women [5] . Therefore, breast cancer should be managed safely and effectively to reduce global comorbidities and mortality.  \nSomatic mutations in tumor protein p53 ( TP53), a tumor suppressor gene, are the most common genetic alterations in diverse malignancies. TP53 mutations occur in approximately 50% of the known cancer types, including breast cancer [6,7] . The murine double-minute 2 protooncogene (MDM2) is a negative regulator of TP53, the primary tumor suppressor protein. Under normal cellular conditions, T","cbCaiebCiGH4P1BH","https://ap.wps.com/l/cbCaiebCiGH4P1BH","pdf",26002468,11,"English","# Introduction\n## Breast cancer burden and pathology overview\n## TP53 mutations and MDM2 as a regulator\n## TP53 pathway functions and clinical rationale","[{\"question\":\"What evidence base does the review draw on, and what limitation is highlighted?\",\"answer\":\"The review examines efficacy using clinical studies, reviews, and trials that address MDM2 inhibition and TP53 restoration. It notes that few clinical and preclinical studies using MDM2 inhibitors have been conducted, requiring high-quality clinical trials to support therapeutic potential.\"}]","Targeting MDM2-p53 interaction for breast cancer therapy - Review | PDF",1790159875,28,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1df00726313a77293e77136dd9d3767f.webp",983,1390,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64079ec6241c74dd09b7252ed3815c73.webp",982,1388,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/377fa168069a1576e5365d0822034357.webp",981,1387,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d283dbc4e50ef4b457bc51922050fb3.webp",980,1385]